Can Seaport’s GlyphAgo overcome agomelatine’s liver problem? New Phase 1 data sharpen the test
Seaport's GlyphAgo shows 6.8-fold higher bioavailability as anxiety trials advance, but its potential to reduce liver risks remains unproven.
Pharma & Biotech